tbuckley/cabot-search huggingface dataset:
818P The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy
Authors: Z.L.R. Kaplan, N. van Leeuwen, D. van Klaveren, F. Eijkenaar, O. Visser, E.F. Posthuma, S. Zweegman, G.A. Huls, A. van Rhenen, N. Blijlevens, J.J. Cornelissen, A.A. van de Loosdrecht, H.F.M. Pruijt, M-D. Levinn, M. Hoogendoorn, V. Lemmens, H.F. Lingsma, A.G. Dinmohamed
Journal: Annals of Oncology (2024)
367P Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer
Authors: E. Rosen, J. Caswell-Jin, D. Berz, N. Mai, G. Fulgar, M. Densel, G. Chiang, S. Sperry, D. Warner, F. Meric-Bernstam
Journal: Annals of Oncology (2024)
353P Clinical outcomes of treatment with CDK4/6 inhibitors in metastatic breast cancer among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2
Authors: R. Scheel, G.M. Choong, R. Koch, S.K. Yadav, A. Karki, R. Rao, N.J. Boddicker, C. Hu, J. Na, V. Kaggal, S. Murphy, K.V. Giridhar, S. Yasir, M.P. Goetz, F.J. Couch, S. Yadav
Journal: Annals of Oncology (2024)
340O Efficacy, safety and biomarker analysis of ICARUS-BREAST01: A phase II study of patritumab deruxtecan (HER3-DXd) in patients (pts) with HR+/HER2- advanced breast cancer (ABC)
Authors: B. Pistilli, L. Pierotti, M. Lacroix-Triki, C. Vicier, J-S. Frenel, V. D'Hondt, F. Dalenc, T. Bachelot, A. Ducoulombier, M-A. Benderra, D. Loirat, D. Mayeur, G.B. Nachabeh, A. Sporchia, F. Suto, S. Michiels, N. Corcos, M.F. Mosele, F. André, G. Montagnac
Journal: Annals of Oncology (2024)
911P Association of genomic landscape and plasma protein dynamic changes with clinical outcome in patients with R/M HNSCC treated with pembrolizumab with nab-paclitaxel and platinum
Authors: X. Chen, W. Zhang, Z. Xie, Y. Zhang, W. Li, T. Xie, J. Yao, H. zhu, L. Tang, Y-K. Shi, L. Gui
Journal: Annals of Oncology (2024)
927P Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancers
Authors: L. Alemany, K-I. Nibu, N. Oridate, E. Morais, C. Roberts, Y-T. Chen, J. Spitzer, M. Roset, M.L. Torres, D. Cuadras, H. Mehanna, H. Mirghani, A. Giuliano, T. Waterboer, M. Pavón
Journal: Annals of Oncology (2024)
944TiP Petosemtamab plus pembrolizumab vs. pembrolizumab alone for first-line (1L) treatment of recurrent/metastatic (r/m) PD-L1–positive head and neck squamous cell carcinoma (HNSCC): A randomized, open-label, phase III trial
Authors: J. Fayette, D.R. Adkins, A. Psyrri, L.L. Siu, M. Tahara, W. Nassib William Junior, R. Pyle, Y-M. Shen, F. Zohren, E. Pennella, E.E. Vokes
Journal: Annals of Oncology (2024)
513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study
Authors: F. Pietrantonio, G.F. Ho, Y-L. Su, E.X. Chen, Y. Yuan, P-J. Voon, X. Liang, D. Jonker, F. Longo Muñoz, J.R. Hecht, S. Chandana, D. Arnold, R. Bhattacharya, J.C. Curtin, S. Maul, R. Iwasawa, S. Chowdhury, R.W. Schnepp, M. Baig, Y.S. Hong
Journal: Annals of Oncology (2024)
1026P Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
Authors: S. Champiat, A. Italiano, N. Wagle, H. Prenen, L. Greillier, H. Bourien, E. Whitman, A-M. Quinson, S. Luecke, V. Hern, U. Lauer
Journal: Annals of Oncology (2024)
924P Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection
Authors: D.W-T. Lim, E. Yeo, J. Neo, E. Ong, W.M. Chow, K.M. Tan, J. Tan, J.P.S. Yeong, T.K.H. Lim, J.S.G. Hwang, Q.S. Ng, Y.L. Soong, M-K. Ang, S.H. Tan, M.L.K. Chua
Journal: Annals of Oncology (2024)
364P Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Authors: E.M. Ciruelos, E.P. Hamilton, S-B. Kim, Y-H. Im, E. Segui Solis, J.Á. García Saenz, A. Di Sanzo, M. Domínguez Lizarbe, T. Wasserman, K.P. Theall, N.K. Ibrahim
Journal: Annals of Oncology (2024)
335P First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors
Authors: F. Lin, Y. Huang, Y. Huang, Y. Lu, X. Rao, X. Wang, F. Wang, X. Huang
Journal: Annals of Oncology (2024)
859P Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to de-escalate surgery and omit adjuvant radiation in locoregionally advanced head &amp; neck squamous cell carcinoma (HNSCC)
Authors: L. Dunn, J. Cracchiolo, A.L. Ho, E.J. Sherman, I. Ganly, R. Ghossein, M. Cohen, W. Wong, A. Desilets, L. Michel, A. Kriplani, T.K.W. Hung, B. Singh, J. Boyle, L. Morris, S. McBride, N. Riaz, N. Lee, R. Wong, D. Pfister
Journal: Annals of Oncology (2024)
372P Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database
Authors: C. Pflumio, M. Carton, M. Debled, P.H. Cottu, M. Leheurteur, F. Dalenc, W. Jacot, A. Mailliez, B. Sauterey, C. Levy, C. Kaderbhai, O. Tredan, A. Gonçalves, L. Uwer, M. Robert, C. Bailleux, L. Cabel, S. Delaloge, L. Bosquet, T. Petit
Journal: Annals of Oncology (2024)
913P Characterisation of genomic biomarkers of response to cetuximab versus cisplatin in concomitance with radiotherapy in locally advanced squamous head and neck cancer
Authors: J.C. Redondo González, A. Olivares Hernandez, J.L. Garcia Hernandez, R. Mesia Nin, J. Rubio Casadevall, C. Garcia Giron, L. Iglesias Docampo, A. Carral Maseda, M. Taberna Sanz, S. Vázquez Fernández, L.A. Corchete Sánchez, N. Gestoso Uzal, R. González Sarmiento, E. Fonseca Sánchez, J.J. Cruz Hernandez, E. del Barco Morillo
Journal: Annals of Oncology (2024)
893P Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial
Authors: Y-F. Jiang, W-X. Bei, L. Wang, C. Xu, N. Lu, H. Liang, L-R. Ke, Y-F. Ye, T. Fang, S. He, S-H. Dong, Q. Liu, C. Zhang, W. Xia, C. Zhao, C. Xie, G. Liu, Y-Q. Xiang
Journal: Annals of Oncology (2024)
313P A longitudinal follow-up study on the prognosis of patients with breast cancer with delayed diagnosis during the COVID-19 pandemic
Authors: J.P. Yi, J.M. Baek, Y-S. Kim, Y.W. Jeon, C.I. Yoon, J. Rhu, S.H. Lim, Y-J. Kang
Journal: Annals of Oncology (2024)
343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial
Authors: M.F. Mosele, A. Lusque, V.C. Dieras, E. Deluche, A. Ducoulombier, B. Pistilli, T. Bachelot, F. Viret, C. Levy, Y.C. Pradat, N. Signolle, L. Le Bescond, D. Tran, N. Droin, M. Kobayashi, T. Kakewaga, M. Deloger, M. Jimenez, M. Lacroix-Triki, F. André
Journal: Annals of Oncology (2024)
872P Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study
Authors: Y. Guo, D.Z. Li, J. Lin, C. Sun, G. Cao, J. Wu, M. Ge, D. Hu, S. Qu, L. Shen, Y. Wei, J. Zong, M. Fang, C. Jin, Z-M. Li, Y. Sun, X. Wang, H. Zhang, W. Wang, Y. Zhu
Journal: Annals of Oncology (2024)
357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC)
Authors: S. Nucera, F. Schettini, F. Giudici, C. Strina, M. Milani, R.J. Tancredi, B. Conte, C. Criscitiello, M. Giuliano, M. Lambertini, R. Sanchez Bayona, T. Pascual, P. Vigneri, G. Arpino, L. Del Mastro, M. Cristofanilli, H.S. Rugo, A. Gennari, G. Curigliano, D. Generali
Journal: Annals of Oncology (2024)
396P Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
Authors: R. Jasuja, D. Raina, R. Ahmad, S. Choudhary, B. Lawney, G. Panchamoorthy, S. Kharbanda
Journal: Annals of Oncology (2024)
1027P First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
Authors: M. Oliva Bernal, L. Greillier, M. Ponz-Sarvise, V. Moreno Garcia, H. Prenen, D. Wolf, A-M. Quinson, S. Luecke, V. Hern, M. Porosnicu
Journal: Annals of Oncology (2024)
877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC
Authors: N.F. Saba, K. Klinghammer, E. Castelluci, A.D. Colevas, T. Rutkowski, D. Thurner, U. Müller-Richter, M. Maio, J.S. Grewal, C.H.H. Ottensmeier, J. Dias, H. Yang, R. Das, J. Furlanetto, A-K. Herzfeldt, M-C. Kühnle, A. Ulges, J. Alles, Ö. Türeci, U. Sahin
Journal: Annals of Oncology (2024)
CN79 Quality-of-Life (QoL) data published by clinical trials supporting drug approvals for renal cell carcinoma (RCC)
Authors: R.E. Seadon, J.C. Tapia, D. Matthews, J. Gavira-Diaz, M. Santoni, M.N. Young, L. Blondel, R. Flippot, G. Anguera, R. Frazer, J.P. Maroto Rey
Journal: Annals of Oncology (2024)
527P Effect of trifluridine/tipiracil (FTD/TPI) in combination with bevacizumab (bev) in patients treated in SUNLIGHT by clinical prognostic factors at baseline
Authors: J. Tabernero, J. Taieb, M. Fakih, F. Ciardiello, E. Van Cutsem, L. Roby, W. Yao, E. Choucair, G. Prager
Journal: Annals of Oncology (2024)
369P Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
Authors: H.S. Rugo, J. O'Shaughnessy, J. Cortés, A. Bardia, E.P. Hamilton, S.A. Hurvitz, V. Kaklamani, W. Mchayleh, P. Muñoz Romero, B. Pizà Vallespir, T. Wasserman, K.P. Theall, S.M. Tolaney
Journal: Annals of Oncology (2024)
519P Cetuximab plus capecitabine versus cetuximab as maintenance treatment in Chinese patients with RAS/BRAF wild type metastatic colorectal cancer (mCRC): A phase III, multicenter, open-label, randomized study (C-CLASSIC study)
Authors: D. Zhang, X. Yuan, Y. Liu, Y. Deng, X. Hu, T. Zhang, Y. Zhang, C. Bai, X. Lin, X. Yin, Z. Liu, T. Liu, H. Zhong, W. Qiu, J. Zhang, R-H. Xu
Journal: Annals of Oncology (2024)
426P Impact of statin therapy on mortality and recurrence in female breast cancer: A meta-analysis
Authors: M.E.C. Souza, L.I.A. de Carvalho, S.J. Lam, J.H.C.O. Cardoso, F.C.A.D. Moraes, L. Rodrigues Fernandes, M. Kreuz, F. Kelly
Journal: Annals of Oncology (2024)
437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
Authors: M. George, J-S. Frenel, J. Cortés, M. Schmidt, J.Á. García Saenz, S. Blau, N.E. Abdulla, M. Nishimura, H. Sakai, S. Babu, N.P. McAndrew, A. Ali, M. Pavic, K. Jhaveri, J.M. Jones, H.S. Rugo, K. Mody, A.D. Smith, T. Yamashita
Journal: Annals of Oncology (2024)
875P A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Authors: D. Ji, Y. Sang, X. Liu, Y. Guo, Y. Yang, G. Chen, S. Dong, Y. Wang, X. He, H. Ying, X. Lu, Y. Wang, C. Hu, Q. Ji
Journal: Annals of Oncology (2024)
CN22 Remote patient monitoring using mHealth technology in cancer care and research: Patients’ perspectives, willingness, and current use
Authors: D. Stuijt, M. Kos, E.E.M. Van Doeveren, I. Dingemans, C. Richel, M. Eversdijk, J. Bosch, A.D. Bins, M. Bak, M. van Oijen
Journal: Annals of Oncology (2024)
930P Real-world data analysis of oncological outcomes in patients with pathological extranodal extension (ENE) in OSCC: A proposal to refine the pathological nodal staging system
Authors: A. Thaduri, H.O. Nemade, S. Chava, J. Gondhi, A. Kumar, C.S.R. Sampathi Rao Leela Mohan
Journal: Annals of Oncology (2024)
921P Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
Authors: M. Saerens, M.J.R. Struys, W. Huvenne, S. Rottey, F. Cordier, S. Fadei, D. Creytens, W. Waelput, T. Vermassen, J. Debacker
Journal: Annals of Oncology (2024)
389P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trial
Authors: H. Li, D. Zhou, Z. Yv, Y. Liao, J. Huang, None S. sun, F. Zheng, B. Li, S. Fang, L. Qiang, None G. ren, X. Wang, Z. Baoxuan, None B. fan, X. Zhao, W. Li, Z. Wang, H. Fu, X. Sun, Z. Shi
Journal: Annals of Oncology (2024)
500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Authors: M. Weller, D.A. Berry, N. Blondin, M. Buxton, H. Colman, J.F. de Groot, M. de la Fuente, F. Ducray, B. Ellingson, G. Gordon, A.B. Lassman, E. Lee, M. Lim, I. Mellinghoff, J. Perry, E. Sulman, W-K.A. Yung, P. Wen, A. Wick, T. Cloughesy
Journal: Annals of Oncology (2024)
880P Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
Authors: T. Fuereder, K. Klinghammer, D.A. Hahn, B. Grünberger, T. Melchardt, R. Greil, F. Kocher, G. Gamerith, C. Wagner, L. Berchtold, M. Burian, A. Strobl
Journal: Annals of Oncology (2024)
317TiP A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer
Authors: Z. Shao, R. Wang, J. Zhang, J. Nie, Y. Yu, Q. Ouyang, J. Huang, C. Xie, None Y. ren, H. Zhang, H. Li, T. Yao, H. Zhang, Y. Yao, S. Li, Q. Cheng, T. Ren, J. Fang
Journal: Annals of Oncology (2024)
909P Immunoscore-IC predicts nivolumab efficacy as adjuvant treatment after salvage surgery in head and neck cancer squamous cell carcinoma: The ADJORL1 trial
Authors: A. Marhic, J. Guerlain, N. Cozic, A. Daste, O. Malard, J. Fayette, F. Rolland, O. Mauvais, A.C. Johnson, S. Salas, M. Vinches, A. Bozec, S. Vergez, E. de Monès, I. Breuskin, M. Iacob, B. Archambaud, A. Marabelle, F. Janot, C. Even
Journal: Annals of Oncology (2024)
947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Authors: L. Rimassa, S.L. Chan, B. Sangro, G. Lau, M. Kudo, V. Breder, M. Varela, O. Crysler, M. Bouattour, V.T. Dao, A. Faccio, J. Furuse, L-B. Jeng, Y-K. Kang, R.K. Kelley, M.J. Paskow, M. Makowsky, D. Ran, A. Negro, G.K. Abou-Alfa
Journal: Annals of Oncology (2024)
346MO Trastuzumab deruxctecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies
Authors: A. Canellas, L. Elu, P. Du Rusquec, M-A. Benderra, L. Drouin, I. Cojean-Zelek, A. Vozy, E. Assaf, A. Teillet Benmaziane, J. Medioni, R. Cohen, L. Zelek, M. Wislez, J. Gligorov, P.Y. Brillet, N. Girard, K. Bihan, J. Cadranel
Journal: Annals of Oncology (2024)
432P Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Authors: N.T. Ueno, N. Niikura, T. Yamashita, W. Jacot, D.A. Cameron, J. Tsurutani, J. Sohn, E. Tokunaga, M.J. Vidal Losada, Y.H. Park, K.S. Lee, Y.S. Chae, A. Prat, F. Suto, Y. Kuwahara, A.D. Boran, M. Kobayashi, V. Kumar, C. Orbegoso Aguilar, S. Modi
Journal: Annals of Oncology (2024)
898P Real-world overall survival (OS) in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) in Asia: A literature review
Authors: D.W-T. Lim, M.L.K. Chua, B.B.Y. Ma, J.S. Evans, Y.R. Wee, M.H. Choi, N. Fujita, S. Dhawan, J. Ng
Journal: Annals of Oncology (2024)
529P Evaluating metastatic disease sites as a prognostic marker in patients receiving sequential treatment with regorafenib and trifluridine/tipiracil for refractory colorectal cancer: Survival outcomes from the multicenter retrospective “ReTrITA” study
Authors: C. Signorelli, M.A. Calegari, A. Anghelone, M. Basso, A. Passardi, G.L. Frassineti, I.V. Zurlo, L. Angotti, M.G. Chilelli, C. Morelli, E. Dell'Aquila, D. Gemma, D.C. Corsi, F. Mazzuca, F. Zoratto, M.G. Morandi, F. Santamaria, R. Saltarelli, M. Dettori, E.M. Ruggeri
Journal: Annals of Oncology (2024)
375P Results from the Danish Breast Cancer Group's (DBCG) NAME-trial: A direct comparison of oral navelbine given either classic or metronomic in metastatic breast cancer
Authors: A.S. Brems-Eskildsen, J. Kenholm, A.T.L. Brixen, J.D. Rønlev, L.E. Stenbygaard, H. Danoe, M. Grunnet, E.H. Jakobsen, J. Neimann, J. Geisler, V. Glavicic, S.T. Langkjer
Journal: Annals of Oncology (2024)
425P The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries
Authors: A.A. Annamalay, G. Cook, M. Wrigglesworth, B. Murphy-Eustis, A. Eniu, R. Ventura, D. Milner, L. Shulman, F. Cardoso, P. Garcia-Gonzalez
Journal: Annals of Oncology (2024)
850MO Phase II randomized trial of chemotherapy followed by surgery and PORT versus surgery and PORT for organ preservation of T3 and T4a (selected T4b) sinonasal squamous cell carcinoma (SNC): A trial of the ECOG-ACRIN cancer research group (EA3163)
Authors: N.F. Saba, Y. Flamand, D.T. Lin, C.H. Chung, M.W. McDonald, S. Flampouri, S.A. Khan, C.H. Snyderman, E. Hanna, Y.H. El-Sayed, C.A. Solares, F. Duan, A.L. Ho, M.A. Samuels, P.L. Swiecicki, R.M. Subramaniam, A. Chakravarthy, B. Burtness
Journal: Annals of Oncology (2024)
386P Exploratory analysis of patients with or without prior PD-(L)1 inhibitors in phase III OptiTROP-Breast01 study of sacituzumab tirumotecan (sac-TMT) versus chemotherapy for previously treated advanced triple-negative breast cancer (TNBC)
Authors: Y. Yin, Y. Fan, Q. Ouyang, L. Song, X. Wang, W. Li, M. Li, X. Yan, S. Wang, T. Sun, Y. Teng, X. Tang, Z. Tong, Z. Sun, X. Jin, Y. Diao, G. Liu, J. Ge, B. Xu
Journal: Annals of Oncology (2024)
902P Comparison of progression free and overall survival (OS) with bicalutamide and 4-weekly or 12-weekly triptorelin in androgen receptor positive (AR+) salivary gland cancer (SGC)
Authors: A.K. Handley, J. Haigh, S. Churchill, S. Rack, K.J. Harrington, K. Patel, L. Spurgeon, R. Metcalf, G. Betts
Journal: Annals of Oncology (2024)
354P Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer
Authors: L. Anders, T. Van Arsdale, S. Chintharlapalli, B. Boras, J. Cianfrogna, N. Huser, B. Pascual, C. Shen, M. Qiu, A. Sacaan, R. Jones
Journal: Annals of Oncology (2024)
370P A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Authors: P. Zhang, B. Xu, T. Sun, Y. Wang, W. Li, Z. Tong, S. Phadke, T.M. Feinstein, J. Qu, P. Guo, W. Ma, M. Zhang, Y. Yue
Journal: Annals of Oncology (2024)
453MO A phase I study for safety, tolerability, pharmacokinetics, and anti-tumor activity of ABM-1310 in patients (pts) with BRAF V600 mutated recurrent primary brain tumours: Interim result
Authors: W. Li, Z. Kang, S. Li, F. Chen, B. Zhang, M. Huang, Z. Yang, C. Chen, Z. Yang
Journal: Annals of Oncology (2024)
906P Prognostic impact and therapeutic implications of comprehensive genomic profiling (CGP) in non-metastatic salivary gland cancers (nmSGC)
Authors: M. Balsa Pena, J. Canet-Hermida, A-A. Izquierdo Miranda, S. Tous, A. Alay Badosa, I. Quintana, E. Purqueras, M. Goma, A. Marí, B. Cirauqui Cirauqui, A. Quer, X. León, N. Baste Rotllan, F. Cuesta, P. Castillo, R.D. Ramírez, M.S. Bescos, C. Lazaro, D. Azuara, M. Oliva Bernal
Journal: Annals of Oncology (2024)
1050P Independent of calendric age, T cells are phenotypically less senescent in successfully ICI-treated cancer patients that developed irAE
Authors: S.L. Roffeis, J. Heuss, A. Bärenwaldt, T. Müller, G.R. Bantug, H. Läubli, C. Hess, V. Hess-Umbricht
Journal: Annals of Oncology (2024)
839P Preliminary results from a phase II study of amulirafusp alfa (IMM0306) in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Authors: J. Yang, Z. Li, M. Zhang, K. Zhou, Y. Li, Y. Yang, Z. Wang, L. Yu, J. Zhang, H. Huang, Y. Cheng, W. Meng, Z. Wang, Q. Lu, W. Tian, Y-K. Shi
Journal: Annals of Oncology (2024)
496P Association of brain metastasis and peritumoral edema volume with the neurological symptom burden in lung cancer patients
Authors: A. Steindl, L. Berchtold, J. Leitner, A. Grisold, F. Eckert, G. Widhalm, M. Preusser, A.S. Berghoff, J. Furtner
Journal: Annals of Oncology (2024)
480P Clinical utility of ctDNA detection by NGS for diagnosis of CNS lymphoma
Authors: A. Jiménez-Ubieto, A. Martín-Muñoz, R. Errazquin, Y. Ruiz-Heredia, L. Rufián, M. Rodríguez, E. Parra, T. Baumann, A. Rodríguez, M.T. Cedena, J. Martinez-Lopez, R. Ayala, I. Rapado
Journal: Annals of Oncology (2024)
418P Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Authors: C. Tsai, J.A-R. An, L. Cabel, A.R. Brannon, E. Moiso, E. Gedvilaite, M. Ahmed, L. Loudon, C. Weipert, J. Chou, M. Capanu, M. Chaki, M. Benrashid, S. Puri, S. Chandarlapaty, D. Ross, S.B. Maron, P. Razavi
Journal: Annals of Oncology (2024)
1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy
Authors: E. Teixidor Vilà, S. Verdura, J.A. Encinar, À. Llop Hernández, È. Sais, A. Hernandez Martinez, A. Romera, J.M. Brunet Vidal, B. Martin-Castillo, E. Lopez-Bonet, J. Bosch-Barrera, E. Cuyàs, J.A. Menendez
Journal: Annals of Oncology (2024)
451MO Final results of glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Authors: M.A. Vaz Salgado, S. del Barco, J.M. Sepúlveda, M. Alonso, E. Pineda, C. Balana, M. Martínez-García, R. Gironés, S. López-Muñoz
Journal: Annals of Oncology (2024)
409P Biological tumor traits predicting late recurrence in premenopausal breast cancer patients: Insights from the STO-5 trial with 20-year follow-up
Authors: J.K.J. De Vos, J. Tutzauer, A. Nordenskjöld, B.A. Nordenskjöld, T. Fornander, G. Pérez Tenorio, O. Stål, N.P. Tobin, L.S. Lindström
Journal: Annals of Oncology (2024)
1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)
Authors: J.W. Riess, J. Spicer, T. Seiwert, V. Villaflor, J. Rubio Perez, P.H. Shaw, A. Soria Rivas, M. Chaney, C. Abildgaard, P. Patel, M. Iglesias, Q. Ahmad, D. McDowell, P. Garrido Lopez
Journal: Annals of Oncology (2024)
918P Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer
Authors: G. Bruixola, J. Martin-Arana, F. Gimeno-Valiente, J.F. Català-Senent, J.A. Carbonell-Asins, C. Alfaro-Cervello, D.G. Camblor, B. Martínez-Castedo, B. García-Mico, N. Grimalt Ferrer, V. Segui-Manzaneque, V. Escorihuela-García, J.L. Léon-Guijarro, M.E. Iglesias, D. Dualde, O. Pons, A. Cervantes, N. Tarazona Llavero
Journal: Annals of Oncology (2024)